Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Wiegand

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
Mbio|April 9, 2021
Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in ChildrenMichael J Bale, Mary Grace Katusiime, Daria Wells, et al.
Scientific Reports|July 6, 2023
Application of ultrasensitive digital ELISA for p24 enables improved evaluation of HIV-1 reservoir diversity and growth kinetics in viral outgrowth assaysYury V Kuzmichev, Carol Lackman-Smith, Sonia Bakkour, et al.
The Journal of Clinical Investigation|September 12, 2017
No evidence of HIV replication in children on antiretroviral therapyGert U Van Zyl, Mary Grace Katusiime, Ann Wiegand, et al.
Plos Medicine|August 17, 2010
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialRajesh T Gandhi, Lu Zheng, Ronald J Bosch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapyRajesh T Gandhi, Robert W Coombs, Ellen S Chan, et al.
Plos Pathogens|April 7, 2007
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremiaFrank Maldarelli, Sarah Palmer, Martin S King, et al.
Frontiers in Microbiology|October 22, 2019
HIV Infected T Cells Can Proliferate <i>in vivo</i> Without Inducing Expression of the Integrated ProvirusAndrew Musick, Jonathan Spindler, Eli Boritz, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNAAdam A Capoferri, Ann Wiegand, Feiyu Hong, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2024
HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNAAdam A Capoferri, Ann Wiegand, Feiyu Hong, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
Mbio|April 9, 2021
Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in ChildrenMichael J Bale, Mary Grace Katusiime, Daria Wells, et al.
Scientific Reports|July 6, 2023
Application of ultrasensitive digital ELISA for p24 enables improved evaluation of HIV-1 reservoir diversity and growth kinetics in viral outgrowth assaysYury V Kuzmichev, Carol Lackman-Smith, Sonia Bakkour, et al.
The Journal of Clinical Investigation|September 12, 2017
No evidence of HIV replication in children on antiretroviral therapyGert U Van Zyl, Mary Grace Katusiime, Ann Wiegand, et al.
Plos Medicine|August 17, 2010
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialRajesh T Gandhi, Lu Zheng, Ronald J Bosch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapyRajesh T Gandhi, Robert W Coombs, Ellen S Chan, et al.
Plos Pathogens|April 7, 2007
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremiaFrank Maldarelli, Sarah Palmer, Martin S King, et al.
Frontiers in Microbiology|October 22, 2019
HIV Infected T Cells Can Proliferate <i>in vivo</i> Without Inducing Expression of the Integrated ProvirusAndrew Musick, Jonathan Spindler, Eli Boritz, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNAAdam A Capoferri, Ann Wiegand, Feiyu Hong, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2024
HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNAAdam A Capoferri, Ann Wiegand, Feiyu Hong, et al.
Pageof 4